India, Feb. 24 -- BioCryst Pharmaceuticals, Inc. (BCRX) posted a net loss for the fourth quarter of $26.8 million, or $0.13 per share, compared to a net loss of $61.7 million, or $0.31 per share, for the fourth quarter of 2023. Analysts on average expected the company to report a loss per share of $0.06, for the quarter. Analysts' estimates typically exclude special items.
Total revenues were $131.5 million, compared to $93.4 million in the fourth quarter of 2023. The company said the increase was primarily due to $124.2 million in ORLADEYO net revenue in the fourth quarter of 2024, compared to $90.9 million inthe fourth quarter of 2023. Analysts on average had estimated $130.05 million in revenue.
The company has increased full year 2025...